<code id='FDEE9C6F6B'></code><style id='FDEE9C6F6B'></style>

<acronym id='FDEE9C6F6B'></acronym>

<center id='FDEE9C6F6B'><center id='FDEE9C6F6B'><tfoot id='FDEE9C6F6B'></tfoot></center><abbr id='FDEE9C6F6B'><dir id='FDEE9C6F6B'><tfoot id='FDEE9C6F6B'></tfoot><noframes id='FDEE9C6F6B'>

<optgroup id='FDEE9C6F6B'><strike id='FDEE9C6F6B'><sup id='FDEE9C6F6B'></sup></strike><code id='FDEE9C6F6B'></code></optgroup>

<b id='FDEE9C6F6B'><label id='FDEE9C6F6B'><select id='FDEE9C6F6B'><dt id='FDEE9C6F6B'><span id='FDEE9C6F6B'></span></dt></select></label></b><u id='FDEE9C6F6B'></u>

~~<i id='FDEE9C6F6B'><strike id='FDEE9C6F6B'><tt id='FDEE9C6F6B'><pre id='FDEE9C6F6B'></pre></tt></strike></i>~~

focus

author hotspot

2025-09-30 08:30:40

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

advertisement

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Vertex cell therapy lets patients with type 1 diabetes stop insulin
Next article： Virginia high school admissions case could be legal follow

Tags

Leave your comment

hotspot

Addressing health care workers' trauma can help fight burnout

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

2025-09-30 05:53

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

entertainment

Virginia high school admissions case could be legal follow

2025-09-30 07:49